Dopamine agonists and cardiac valvulopathy in Parkinson disease: a case-control study.
Senol
Mehmet G
MG
Togrol
R Erdem
RE
D000978:Antiparkinson Agents / Q000009:adverse effects* / Q000627:therapeutic use; D052160:Benzothiazoles / Q000009:adverse effects / Q000627:therapeutic use; D000077465:Cabergoline; D016022:Case-Control Studies; D018491:Dopamine Agonists / Q000009:adverse effects* / Q000627:therapeutic use; D004873:Ergolines / Q000009:adverse effects*; D005260:Female; D006349:Heart Valve Diseases / Q000139:chemically induced*; D006801:Humans; D008297:Male; D010300:Parkinson Disease / Q000150:complications / Q000188:drug therapy*; D018579:Patient Selection; D010479:Pergolide / Q000009:adverse effects / Q000627:therapeutic use; D000077487:Pramipexole; D012107:Research Design; D012737:Sex Factors
D000978:Antiparkinson Agents; D052160:Benzothiazoles; D018491:Dopamine Agonists; D004873:Ergolines; D010479:Pergolide; D000077487:Pramipexole; D000077465:Cabergoline